{"id":"double-atorvastatin","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Muscle pain or myalgia"},{"rate":"1-3%","effect":"Elevated liver enzymes"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"},{"rate":"<0.1%","effect":"Rhabdomyolysis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This leads to decreased hepatic cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. The term 'Double' likely refers to a fixed-dose combination or enhanced formulation, though the core mechanism remains HMG-CoA reductase inhibition.","oneSentence":"Double Atorvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:35:33.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT07045142","phase":"PHASE3","title":"Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-07-01","conditions":"Schizophrenia","enrollment":400},{"nctId":"NCT06308952","phase":"PHASE4","title":"Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation","status":"RECRUITING","sponsor":"Duan Chuanzhi","startDate":"2024-07-30","conditions":"Cerebrovascular Event, Stent Stenosis, Ischemic Stroke","enrollment":354},{"nctId":"NCT07268625","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-12-09","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07235189","phase":"PHASE1","title":"A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-28","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT04679376","phase":"PHASE2","title":"Statins for the Treatment of NASH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-01-25","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":70},{"nctId":"NCT07278830","phase":"PHASE2","title":"A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2023-06-02","conditions":"Hypercholesterolemia and Mixed Dyslipidemia","enrollment":214},{"nctId":"NCT07042165","phase":"PHASE4","title":"Treatment of Bile Acid Diarrhoea With Atorvastatin","status":"RECRUITING","sponsor":"Asger Lund, MD","startDate":"2025-10-15","conditions":"Bile Acid Diarrhea, Bile Acid Malabsorption","enrollment":20},{"nctId":"NCT06336174","phase":"","title":"Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2022-11-01","conditions":"Intracranial Atherosclerosis, Cognitive Impairment, Cerebrovascular Event","enrollment":100},{"nctId":"NCT05028829","phase":"PHASE2","title":"Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk","status":"RECRUITING","sponsor":"Raymond Chung","startDate":"2023-05-10","conditions":"Liver Fibroses, Cirrhosis","enrollment":60},{"nctId":"NCT07128212","phase":"NA","title":"Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1","status":"COMPLETED","sponsor":"Suzhou Municipal Hospital of Anhui Province","startDate":"2021-01-01","conditions":"Ischemic White Matter Lesions (WMIL), Cerebral Small Vessel Disease, Vascular Cell Adhesion Molecule-1","enrollment":401},{"nctId":"NCT07008794","phase":"","title":"Effect of Genetic Variation on Efficacy and Safety of Lipid-Lowering Drugs","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-04-01","conditions":"Acute Coronary Syndromes","enrollment":200},{"nctId":"NCT06974084","phase":"PHASE2, PHASE3","title":"Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).","status":"NOT_YET_RECRUITING","sponsor":"HealthBio, Inc.","startDate":"2025-09-01","conditions":"Long COVID","enrollment":252},{"nctId":"NCT04824911","phase":"PHASE2","title":"Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-23","conditions":"Acute Stroke, Dual Antiplatelet Therapy, Statin","enrollment":376},{"nctId":"NCT03024684","phase":"PHASE4","title":"Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiayi Christian Hospital","startDate":"2017-01-03","conditions":"HepatoCellular Carcinoma","enrollment":240},{"nctId":"NCT05930028","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2023-07-13","conditions":"Essential Hypertension, Primary Hypercholesterolemia","enrollment":148},{"nctId":"NCT04147286","phase":"PHASE2, PHASE3","title":"Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion","status":"RECRUITING","sponsor":"University of Cape Town","startDate":"2020-07-14","conditions":"Tuberculosis, Pulmonary","enrollment":220},{"nctId":"NCT00541697","phase":"PHASE3","title":"Eze/Simva Switch Study in Diabetics (0653A-807)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-19","conditions":"Diabetes Mellitus, Type 2","enrollment":648},{"nctId":"NCT00092638","phase":"PHASE3","title":"An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":450},{"nctId":"NCT00092625","phase":"PHASE3","title":"Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-03","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":442},{"nctId":"NCT00092716","phase":"PHASE3","title":"Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-05","conditions":"Hypercholesterolemia","enrollment":655},{"nctId":"NCT00132717","phase":"PHASE3","title":"A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Hypercholesterolemia","enrollment":450},{"nctId":"NCT00110435","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-05","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":1229},{"nctId":"NCT00651378","phase":"PHASE4","title":"Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2004-09-01","conditions":"Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease","enrollment":87},{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00090168","phase":"PHASE3","title":"Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01-27","conditions":"Hypercholesterolemia, Atherosclerotic Disease, Coronary Disease","enrollment":435},{"nctId":"NCT05327595","phase":"PHASE1","title":"A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-05-09","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT00782184","phase":"PHASE3","title":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT00418834","phase":"PHASE3","title":"Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia","enrollment":1053},{"nctId":"NCT00276484","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":579},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT03867110","phase":"PHASE3","title":"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-06","conditions":"Hypercholesterolemia","enrollment":628},{"nctId":"NCT00092690","phase":"PHASE3","title":"MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-06","conditions":"Hypercholesterolemia","enrollment":1902},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT06239714","phase":"PHASE1","title":"A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)","status":"UNKNOWN","sponsor":"Suzhou Sanegene Bio Inc.","startDate":"2024-02-18","conditions":"Hyperlipidemias","enrollment":64},{"nctId":"NCT04591808","phase":"PHASE3","title":"Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia","status":"TERMINATED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2021-09-09","conditions":"Dyslipidemias, Hypertension","enrollment":146},{"nctId":"NCT05996978","phase":"","title":"Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis","status":"COMPLETED","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2020-02-01","conditions":"Ischemic Stroke","enrollment":42},{"nctId":"NCT05970679","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-08-17","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":252},{"nctId":"NCT03635749","phase":"PHASE3","title":"Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2018-09-17","conditions":"Acute Stroke, Transient Ischemic Attack","enrollment":6100},{"nctId":"NCT01710007","phase":"PHASE3","title":"Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2011-11","conditions":"Hypercholesterolemia","enrollment":202},{"nctId":"NCT02947620","phase":"PHASE3","title":"Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2015-08","conditions":"Type II Diabetes, Dyslipidemia","enrollment":185},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT05049603","phase":"PHASE3","title":"A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study","status":"NOT_YET_RECRUITING","sponsor":"University of Pisa","startDate":"2024-01-01","conditions":"Graves' Orbitopathy","enrollment":102},{"nctId":"NCT04072601","phase":"PHASE4","title":"Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis","status":"TERMINATED","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2019-11-08","conditions":"Liver Cirrhoses","enrollment":78},{"nctId":"NCT05620615","phase":"","title":"Intensive Drug Therapy for Ischemic Stroke","status":"UNKNOWN","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2018-07-01","conditions":"Ischemic Stroke","enrollment":42},{"nctId":"NCT00127335","phase":"PHASE4","title":"Is Myopathy Part of Statin Therapy (IMPOSTER-16)","status":"WITHDRAWN","sponsor":"Scripps Health","startDate":"2005-08","conditions":"Myopathic Conditions","enrollment":""},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT01516879","phase":"PHASE3","title":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01-05","conditions":"Hypercholesterolemia","enrollment":905},{"nctId":"NCT05131997","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2021-11-16","conditions":"Primary Hypercholesterolemia","enrollment":290},{"nctId":"NCT04718155","phase":"NA","title":"Could Early Atorvastatin Offer Anti Inflammatory Effects Upon Brain in Traumatic Head Injury?","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-03-01","conditions":"Traumatic Brain Injury","enrollment":30},{"nctId":"NCT00715273","phase":"PHASE4","title":"Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication","status":"COMPLETED","sponsor":"University of Washington","startDate":"2001-05-01","conditions":"Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis","enrollment":217},{"nctId":"NCT05395143","phase":"PHASE2","title":"Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-05-01","conditions":"Hyperlipidemias","enrollment":92},{"nctId":"NCT03882996","phase":"PHASE3","title":"A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-06","conditions":"Hypercholesterolemia","enrollment":432},{"nctId":"NCT01370603","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":328},{"nctId":"NCT01154036","phase":"PHASE3","title":"MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-07","conditions":"Hypercholesterolemia","enrollment":1547},{"nctId":"NCT01370590","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09","conditions":"Hypercholesterolemia","enrollment":406},{"nctId":"NCT00652327","phase":"PHASE4","title":"Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":83},{"nctId":"NCT03186404","phase":"PHASE2","title":"Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2018-05-10","conditions":"Cancer, Heart Failure, Cardiotoxicity","enrollment":112},{"nctId":"NCT01759836","phase":"PHASE2","title":"Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2012-10","conditions":"Prostatic Neoplasms","enrollment":364},{"nctId":"NCT03956368","phase":"PHASE3","title":"Efficacy of Atorvastatin in Chronic Subdural Haematoma","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2020-01-09","conditions":"Chronic Subdural Hematoma","enrollment":690},{"nctId":"NCT04952350","phase":"PHASE3","title":"Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-08-14","conditions":"Covid19, SARS-CoV2 Infection, COVID-19 Pneumonia","enrollment":220},{"nctId":"NCT05072054","phase":"PHASE4","title":"Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2019-10-16","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":80},{"nctId":"NCT02586155","phase":"PHASE3","title":"Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD","status":"COMPLETED","sponsor":"Resverlogix Corp","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":2425},{"nctId":"NCT01351025","phase":"PHASE2","title":"Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-04-14","conditions":"HIV-1 Infection","enrollment":98},{"nctId":"NCT02714569","phase":"PHASE1","title":"A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Dyslipidemias","enrollment":60},{"nctId":"NCT04850001","phase":"","title":"Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study","status":"UNKNOWN","sponsor":"Anhui Medical University","startDate":"2020-09-10","conditions":"Magnetic Resonance Imaging, Asymptomatic Intracranial Stenosis, Medical Treatment","enrollment":40},{"nctId":"NCT02497638","phase":"PHASE2","title":"LIpitor and biGuanide to Androgen Delay Trial","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2021-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00739999","phase":"PHASE1","title":"8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-12","conditions":"Pediatric Heterozygous Hypercholesterolemia","enrollment":39},{"nctId":"NCT00644709","phase":"PHASE4","title":"A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-09","conditions":"Dyslipidemias","enrollment":196},{"nctId":"NCT00644670","phase":"PHASE4","title":"A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-06","conditions":"Dyslipidemias","enrollment":232},{"nctId":"NCT00151502","phase":"PHASE3","title":"To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-11","conditions":"Alzheimer's Disease","enrollment":600},{"nctId":"NCT00640549","phase":"PHASE4","title":"Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-03","conditions":"Hyperlipidemia, Diabetes Mellitus, Type 2, Non-Insulin Dependent Diabetes Mellitus","enrollment":41},{"nctId":"NCT00141232","phase":"PHASE4","title":"Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Diabetes, Type 2","enrollment":810},{"nctId":"NCT00163202","phase":"PHASE4","title":"Comparative Atorvastatin Pleiotropic Effects","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-06","conditions":"Coronary Arteriosclerosis, Hypercholesterolemia","enrollment":330},{"nctId":"NCT04754789","phase":"PHASE3","title":"Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02-20","conditions":"ST Elevation Myocardial Infarction","enrollment":160},{"nctId":"NCT00412113","phase":"PHASE4","title":"A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-01","conditions":"Dyslipidemia, Hypertension","enrollment":245},{"nctId":"NCT04744571","phase":"NA","title":"Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2021-02","conditions":"Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention","enrollment":200},{"nctId":"NCT00159718","phase":"PHASE4","title":"Double Blind Atorvastatin Amlodipine Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-07","conditions":"Angina","enrollment":360},{"nctId":"NCT00174330","phase":"PHASE4","title":"Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-05","conditions":"Hypertension, Hyperlipidemia","enrollment":330},{"nctId":"NCT00332761","phase":"PHASE4","title":"Caduet in an Untreated Subject Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-06","conditions":"Hypertension, Dyslipidemia","enrollment":220},{"nctId":"NCT04601116","phase":"PHASE3","title":"The MASTER Study (MAmmary Cancer STatin ER Positive Study)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2021-01-04","conditions":"Breast Cancer Female, Estrogen Receptor Positive Tumor","enrollment":3360},{"nctId":"NCT00375518","phase":"NA","title":"Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-07","conditions":"Thoracic Surgery","enrollment":162},{"nctId":"NCT01859455","phase":"PHASE1","title":"Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Hypercholesterolemia, LDL Cholesterol","enrollment":25},{"nctId":"NCT04221321","phase":"PHASE1","title":"Effect of Tegoprazan or RAPA114 on Pharmacokinetic of Atorvastatin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-01-07","conditions":"Healthy","enrollment":32},{"nctId":"NCT03372785","phase":"","title":"The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2018-04-10","conditions":"Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention, Coronary Artery Disease","enrollment":240},{"nctId":"NCT01709513","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-09-30","conditions":"Hypercholesterolemia","enrollment":314},{"nctId":"NCT02591836","phase":"PHASE2","title":"Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin","status":"COMPLETED","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2003-01","conditions":"Hypercholesterolemia","enrollment":277},{"nctId":"NCT03051100","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-01-19","conditions":"Hypercholesterolemia","enrollment":63},{"nctId":"NCT00233480","phase":"PHASE4","title":"Statin Therapy in Heart Failure: Potential Mechanisms of Benefit","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Heart Failure, Congestive","enrollment":27},{"nctId":"NCT02029118","phase":"EARLY_PHASE1","title":"Acupoint Application in Patients With Stable Angina Pectoris (AASAP)","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-10","conditions":"Stable Angina Pectoris","enrollment":200},{"nctId":"NCT00504829","phase":"PHASE2","title":"Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2007-07","conditions":"Dyslipidemia","enrollment":220},{"nctId":"NCT04101136","phase":"NA","title":"Effect of Atorvastatin on Subclinical Atherosclerosis","status":"UNKNOWN","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2019-09-30","conditions":"CMV","enrollment":80},{"nctId":"NCT03338426","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-01-15","conditions":"Essential Hypertension, Dyslipidemia","enrollment":133},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT02938949","phase":"PHASE4","title":"Alirocumab in Patients With Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-01","conditions":"Myocardial Infarction, Hypercholesterolemia","enrollment":20},{"nctId":"NCT03532620","phase":"PHASE4","title":"China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension","status":"UNKNOWN","sponsor":"Jun Tao","startDate":"2018-08-09","conditions":"Prediabetic State, Hypertension, Dyslipidemias","enrollment":396},{"nctId":"NCT01779453","phase":"PHASE2","title":"A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2012-12","conditions":"Hypercholesterolemia","enrollment":58},{"nctId":"NCT02072161","phase":"PHASE2","title":"Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lipitor"],"phase":"marketed","status":"active","brandName":"Double Atorvastatin","genericName":"Double Atorvastatin","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Double Atorvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}